Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

H2S preconditioning of human adipose tissue-derived stem cells increases their efficacy in an in vitro model of cell therapy for simulated ischemia.

Dongó E., Benkő Z., Csizmazia Á., Marosi G., Grottke A., Jücker M.

Animal Study on Cardiovascular Disease, published in Life Sci (2014) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Life Sci (2014)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
25072356
DOI
10.1016/j.lfs.2014.07.023
Citations
14

Abstract (original English)

Aims A major limitation of cell-based therapies for ischemia-reperfusion injury is the excessive loss of administered cells. We investigated whether H2S can improve the survival and efficacy of therapeutic cells in an in vitro model of cell-based therapy for simulated ischemia. Main methods H9c2 rat cardiomyoblasts were exposed to oxygen-glucose deprivation and NaHS (3-30 μM) pretreated human adipose tissue derived stem cells (hASCs) were added after reoxygenization. Viability of both cell lines was assessed with flow cytometry after 24h. The effects of H2S on antioxidant defense, proliferation, AKT and ERK1/2 phosphorylation and mitochondrial activity were analyzed in hASCs. Proliferation was evaluated using propargylglycine, an inhibitor of endogenous H2S synthesis. Key findings NaHS pretreatment decreased the ratio of necrotic therapeutic cells by 41.8% in case of 3 μM NaHS and by 34.3% with 30 μM NaHS. The ratio of necrotic postischemic cardiomyocytes decreased by 35%, but only with the use of 3 μM NaHS. Antioxidant defense mechanisms and ERK-phosphorylation were enhanced after 3 μM NaHS treatment while AKT-phosphorylation was suppressed. NaHS dose-dependently increased the proliferation of hASCs while pretreatment with propargylglycine decreased it. Significance NaHS pretreatment can increase the survival of therapeutically used human adipose tissue-derived stem cells via

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAdultAlkynesAnimalsAntioxidantsCell LineCell ProliferationCell SurvivalFemaleGasotransmitters

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research